Elixir Pharmaceuticals develops and commercializes pharmaceuticals for the treatment of metabolic diseases.
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 19, 2009 | Series D | $12M | 1 | — | — | Detail |
Nov 27, 2006 | Debt Financing | $15M | 1 | — | — | Detail |
Nov 27, 2006 | Series C | $31M | 2 | — | — | Detail |
Oct 13, 2003 | Series B | $40.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series D |
Hercules Capital | — | Debt Financing |